Treatment with 90Y/177Lu DOTATOC in patients with metastatic adrenocortical carcinoma expressing somatostatin receptors

Salvatore Grisanti, Angelina Filice, Vittoria Basile, Deborah Cosentini, Ida Rapa, Domenico Albano, Alessandra Morandi, Marta Laganà, Alberto Dalla Volta, Francesco Bertagna, Guido M A Tiberio, Marco Volante, Massimo Terzolo, Annibale Versari, Alfredo Berruti

Research output: Contribution to journalArticle

Abstract

CONTEXT: We investigated the role of 68Ga-DOTATOC PET/CT in detecting somatostatin receptors (SSTRs) in 19 patients with metastatic adrenocortical carcinoma (ACC) and explored the activity of 90Y/177Lu-DOTATOC Peptide Receptor Radionuclide Therapy (PRRT).

CASE DESCRIPTION AND METHODS: 68Ga uptake in metastatic sites was scored in terms of intensity and anatomical uptake distribution of standard uptake value (SUV). Tissue expression of SSTR2A and SSTR5 was also evaluated by immunohistochemistry (IHC) on primary tumors. Eight patients (42%) displayed radiometabolic uptake of any grade intensity with focal and limited distribution. Two patients (11%) displayed strong uptake in multiple lesions and were treated with PRRT. Both obtained an overall disease control lasting 4 and 12 months, respectively.

CONCLUSIONS: ACC can express SSTRs as detected by IHC and 68Ga-DOTATOC PET. SSTRs-based PRRT may represent a potential treatment opportunity for a minority of advanced ACC patients. This treatment modality deserves further investigation.

Original languageEnglish
JournalThe Journal of clinical endocrinology and metabolism
DOIs
Publication statusE-pub ahead of print - Oct 21 2019

Fingerprint Dive into the research topics of 'Treatment with 90Y/177Lu DOTATOC in patients with metastatic adrenocortical carcinoma expressing somatostatin receptors'. Together they form a unique fingerprint.

  • Cite this

    Grisanti, S., Filice, A., Basile, V., Cosentini, D., Rapa, I., Albano, D., Morandi, A., Laganà, M., Dalla Volta, A., Bertagna, F., Tiberio, G. M. A., Volante, M., Terzolo, M., Versari, A., & Berruti, A. (2019). Treatment with 90Y/177Lu DOTATOC in patients with metastatic adrenocortical carcinoma expressing somatostatin receptors. The Journal of clinical endocrinology and metabolism. https://doi.org/10.1210/clinem/dgz091